Merck KGaA (MKGAY) said in its annual report this morning: “On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics (SWTX), Inc., USA. At the time of the preparation of the Consolidated Financial Statements, there existed no certainty that a merger agreement would be signed.” Barclays this morning pointed out that SpringWorks cancelled this morning from its conference next week, following cancellations from other public events since the neurofibromatosis type one approval on February 11. Shares of SpringWorks are down 19c to $50.40 in premarket trading.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks cancelled from conference this week, says Barclays
- SpringWorks Therapeutics price target lowered to $77 from $78 at Guggenheim
- SpringWorks Therapeutics Reports Strong 2024 Performance
- SpringWorks Therapeutics reports FY24 EPS ($3.48), consensus ($3.16)
- SpringWorks, Jennifer Fisher team to increase understanding of desmoid tumors
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue